Merck & Co., Inc. (MRK) rises 5.6% on oncology wins
May 25, 20265 min read
Key Takeaway
Merck & Co., Inc. (MRK) rose 5.6% as investors reacted to two oncology catalysts: positive Phase 3 data for sacituzumab tirumotecan plus Keytruda in advanced lung cancer and a favorable EU CHMP opinion for Keytruda plus Padcev. The move signals growing confidence that Merck can keep expanding its cancer franchise, which supports the stock’s premium valuation and long-term growth case for investors.
Merck & Co., Inc. (MRK) rises sharply after a pair of oncology headlines gave investors a concrete reason to bid up the stock. Shares closed at $122.41, up 5.64%, with volume running at 1.3x normal, a notable move for a $302.33B drugmaker sitting near its 52-week high of $124.22.
Key Takeaways
•
MRK jumped 5.64% to $122.41 on above-average volume, with relative volume at 1.3x.
•
The clearest catalyst was positive Phase 3 data from the OptiTROP-Lung05 trial, where sacituzumab tirumotecan plus Keytruda beat Keytruda alone in advanced non-small cell lung cancer.
•
A second boost came from a positive EU CHMP opinion for Keytruda plus Padcev in cisplatin-ineligible resectable muscle-invasive bladder cancer.
•
The news matters because Keytruda remains central to Merck's business, with combined global sales of Keytruda and Keytruda Qlex up 12% in Q1 2026.
•
For investors, the rally points to a market that is rewarding Merck for extending its oncology franchise beyond a single blockbuster asset.
Why Merck & Co., Inc. Stock Is Rising Today
The strongest reason behind MRK's move is a late-stage cancer trial win. Merck reported positive interim Phase 3 results from OptiTROP-Lung05, showing that sacituzumab tirumotecan, or sac-TMT, plus Keytruda outperformed Keytruda alone in advanced non-small cell lung cancer.
That is the kind of update the market takes seriously. Phase 3 oncology data can change revenue expectations fast, especially when it strengthens a franchise built around one of the biggest cancer drugs in the world. In plain English, Merck did not just add another headline. It added evidence that its next layer of oncology growth has real weight.
Reuters-linked coverage tied the stock's morning jump directly to that lung cancer result, with shares up nearly 4.7% in early trading on the news. That lines up cleanly with the broader 5.64% daily gain.
The second headline matters too. On May 22 at 7:55 a.m. EDT, Merck said the European Medicines Agency's CHMP adopted a positive opinion for Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer.
This is not just regulatory housekeeping. For big pharma, every new label expansion helps stretch the life and reach of a flagship drug. Keytruda already anchors Merck's oncology business, so another step toward broader use in Europe gives investors a fresh reason to assign value to the franchise.
Together, the lung cancer data and the bladder cancer regulatory milestone created a one-two punch. One item showed pipeline strength. The other showed commercial runway. Markets tend to pay up when both show up on the same morning.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The rally also lands on top of a business that has been executing well enough to earn the benefit of the doubt. Merck's trailing EPS stands at 3.55, and the stock trades at a P/E of 34.48. That is not cheap in a vacuum, but investors often accept a richer multiple when a drugmaker keeps producing meaningful oncology data.
Recent earnings history adds support. Merck has beaten EPS estimates in six straight reported quarters. The most recent quarter on April 30, 2026 showed EPS of -1.28 versus a -1.50 estimate, a 14.7% upside surprise. Before that, the company posted EPS of 2.04 on Feb. 3, 2026, topping the 2.0105 estimate.
There is also a useful balance in MRK's profile. The dividend yield is 2.83%, and the beta is 0.195. So while the company is still tied to drug development risk, the stock does not trade like a pure biotech science project. It trades more like a defensive compounder that occasionally gets a shot of adrenaline from strong trial data.
Analyst sentiment has also leaned constructive this year. Wells Fargo carries a $150 target, Deutsche Bank upgraded the stock to Buy in February, and the broader analyst consensus is Buy with a $129.31 average target. After the latest move to $122.41, that consensus still leaves room above the last close, though not a massive gap.
The market's logic here is straightforward. Merck needs to keep broadening its oncology bench because Keytruda is both its crown jewel and its concentration risk. In Q1 2026, combined global sales of Keytruda and Keytruda Qlex grew 12%, which confirms the franchise still has force.
That same fact also explains why new combinations matter so much. Positive Phase 3 data for sac-TMT plus Keytruda gives investors a more concrete path to extending Merck's cancer leadership. Meanwhile, the CHMP opinion on Keytruda plus Padcev adds another brick to the wall. Drug pipelines are rarely linear, but this is the sort of progress that helps a company defend its moat rather than merely talk about it.
Actionably, MRK now looks more like a momentum-backed quality name than a sleepy pharma hold. Still, after a 5.64% jump and a close near the 52-week high, investors chasing the move should weigh the stock's 34.48 P/E against how much of this oncology optimism is now reflected in the price. Existing holders, by contrast, just got a reminder that pipeline wins can still re-rate a mature pharma giant.
Merck's rally was not random. It was driven by positive Phase 3 lung cancer data and a favorable European regulatory step for a Keytruda regimen, both of which reinforce the strength of its oncology engine. For investors, that keeps MRK in the camp of large-cap healthcare stocks with both defensive traits and real catalyst power.
MRK is up because Merck reported positive Phase 3 lung cancer data for sacituzumab tirumotecan plus Keytruda and also received a favorable EU regulatory opinion for Keytruda plus Padcev. Those updates strengthen confidence in Merck’s oncology pipeline and future sales potential.
+Should I buy MRK stock now?
The article supports Merck as a quality large-cap healthcare name with real pipeline momentum, but the stock is now near its 52-week high after a sharp jump. Long-term investors may still like the story, while short-term buyers should be mindful of valuation and near-term upside already priced in.
+What was the main catalyst for Merck's stock gain?
The main catalyst was positive interim Phase 3 data from the OptiTROP-Lung05 trial, where sacituzumab tirumotecan plus Keytruda beat Keytruda alone in advanced non-small cell lung cancer. That was reinforced by a second headline involving a positive EU CHMP opinion for another Keytruda combination.
+Does this move change Merck's long-term outlook?
Yes, it improves the long-term outlook by showing Merck can keep broadening its oncology franchise beyond Keytruda alone. If these pipeline and regulatory wins continue, they can help support growth and defend the company’s market position.
Want the full picture on MRK?
Read the analyst-grade research report — charts, grades, and price targets.
